Minocycline improves autism-related behaviors by modulating microglia polarization in a mouse model of autism.

Researchers tested an antibiotic called minocycline in mice that show autism-like behaviors. The medication improved the mice's social skills and reduced repetitive behaviors. It also appeared to reduce brain inflammation and help brain cell growth. While these results are promising, this is only an animal study, so we don't yet know if minocycline would help people with autism.

This preclinical study investigated minocycline, an antibiotic with anti-inflammatory properties, as a potential treatment for autism spectrum disorder using the BTBR mouse model. Researchers found that minocycline administration improved social behaviors and reduced repetitive stereotyped behaviors in BTBR mice, while having no effect on control mice. The treatment also enhanced neurogenesis and reduced microglial activation in the hippocampus, suggesting neuroinflammation modulation as a mechanism. Additionally, minocycline inhibited Erk1/2 phosphorylation, indicating effects on cellular signaling pathways.

These findings suggest minocycline may address core autism symptoms through anti-inflammatory and neuroprotective mechanisms, though translation to human autism requires further investigation.

While promising for understanding neuroinflammation in autism, this preclinical evidence requires human clinical trials before considering minocycline as an autism treatment. Healthcare providers should not prescribe minocycline for autism based solely on these animal model results.

This is a preclinical animal study using only one autism mouse model. Sample sizes are not reported, and findings may not translate to human autism. The study lacks long-term follow-up data and doesn't address potential side effects or optimal dosing strategies.

Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder with few pharmacological treatments. Minocycline, a tetracycline derivative that inhibits microglial activation, has been well-identified with anti-inflammatory properties and neuroprotective effects. A growing body of research suggests that ASD is associated with neuroinflammation, abnormal neurotransmitter levels, and neurogenesis. Thus, we hypothesized that minocycline could improve autism-related behaviors by inhibiting microglia activation and altering neuroinflammation.

To verify our hypothesis, we used a mouse model of autism, BTBR T + Itpr3tf/J (BTBR). As expected, minocycline administration rescued the sociability and repetitive, stereotyped behaviors of BTBR mice while having no effect in C57BL/6J mice. We also found that minocycline improved neurogenesis and inhibited microglia activation in the hippocampus of BTBR mice. In addition, minocycline treatment inhibited Erk1/2 phosphorylation in the hippocampus of BTBR mice.

Our findings show that minocycline administration alleviates ASD-like behaviors in BTBR mice and improves neurogenesis, suggesting that minocycline supplementation might be a potential strategy for improving ASD symptoms.